Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...
“Arcturus is actively engaged with the U.S. government to prepare for the next pandemic, and clearance to proceed into the clinic with our STARR® self-amplifying mRNA technology is a key step in this ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...
Hosted on MSN9h
Novavax to Report Q3 Earnings: Here's What to ExpectNovavax NVAX is scheduled to report third-quarter 2024 earnings on Nov. 12, before the opening bell. In the last reported ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Production tips from Crystal Bio, TriLink Biotechnologies, Ginkgo Bioworks, Quantoom Biosciences, and Parexel.
Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older – ...
Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback